PVLA
PALVELLA THERAPEUTICS, INC.
Next earnings Aug 12, 2026 · consensus $-1.12 EPS
Last earnings -13.0% on 2026-05-07
$148.21
▲ +8.82%$148.21▲ +557.54%
over 1Y
L $20.62EODHDH $148.34
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+8.8%
1W+24.7%
1M+27.5%
3M+31.9%
YTD+47.8%
1Y+557.5%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 23 analysts
Buy
Revenue grew 65.3% YoY; but unprofitable (net margin -97.4%).
Revenue (FY2023) $42.8M · FY2023
PALVELLA THERAPEUTICS, INC. shows $42.8M in FY2023 revenue (+65.3% YoY), a -97.4% net margin, and -149.1% ROE.
Financials · annual, by fiscal year
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $31.4M | $25.9M | $42.8M | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$51.8M | -$43.5M | -$11.9M | -$14.1M | -$38.6M |
| Net income | -$45.7M | -$33.3M | $18.7M | -$17.4M | -$41.7M |
| Diluted EPS | -$0.71 | — | $2.17 | -$7.83 | -$3.71 |
| Net margin | -145.6% | -128.5% | 43.7% | — | — |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$2.06B
EV / EBITDA—
EV / Sales48.2
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield-2.0%
FCF yield-1.2%
Quality & risk
ROIC (est.)-109.0%
Free cash flow-$25.2M
Total debt—
Net cash$58.0M
Altman Z-Score36.67 safe
Piotroski F-Score2/7
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+29.9%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Disclosure timeline
SEC · 8-Ks + reportsSome governance/structural items recently, but no outright red flags.
Recent filings
all on EDGAR ↗4Period ending 2026-06-172026-06-22open ↗144Filing2026-06-17open ↗4Period ending 2026-06-122026-06-16open ↗8-KPeriod ending 2026-06-102026-06-16open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-06-102026-06-12open ↗4Period ending 2026-05-202026-05-22open ↗144Filing2026-05-20open ↗
Frequently asked
- Is PALVELLA THERAPEUTICS, INC. (PVLA) a buy?
- PVLA currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Revenue grew 65.3% YoY; but unprofitable (net margin -97.4%).
- What is PALVELLA THERAPEUTICS, INC.'s quality score?
- PVLA scores 38.09803921568627/100 (grade F) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001583648, latest 10-Q filed 2026-05-07) · EODHD · as of 6/22/2026, 10:54:47 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.